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Results
In scenario one, the total costs were SGD 226.41 with aprepitant and ondansetron, SGD 143.27 with ondansetron, or SGD 140.97 with granisetron. The total QALYs were 0.00967 with aprepitant, and 0.00796 without it (with ondansetron or granisetron). The incremental cost per QALY gained with the aprepitant was SGD 48,440 compared with ondansetron alone, or SGD 49,778 compared with granisetron.
In scenario two, the total costs were SGD 223.65 with aprepitant and ondansetron, SGD 168.35 with ondansetron, and SGD 201.39 with granisetron. The total QALYs were 0.00988 with aprepitant, and 0.00894 with ondansetron or granisetron. The incremental cost per QALY gained with the aprepitant was SGD 58,719 compared with ondansetron, or SGD 22,636 compared with granisetron.
In scenario three, the total costs were SGD 124.08 with aprepitant and ondansetron, SGD 97.95 with ondansetron, and SGD 133.29 with granisetron. The total QALYs were 0.0092 with aprepitant and 0.0080 with ondansetron or granisetron. The incremental cost per QALY gained with the aprepitant was SGD 21,421 compared with ondansetron, or it was cost saving compared with granisetron.
The sensitivity analysis showed that the results were robust to changes in the model inputs.
